US EditionPROREIT ANNOUNCES FOURTH QUARTER AND FISCAL YEAR 2024 RESULTS
- Nektar Therapeutics reported a fourth-quarter revenue of $29.2 million for 2024, up from $23.9 million in the previous year, with total operating costs decreasing significantly to $14.8 million from $57.4 million.
- Nektar's cash and marketable securities totaled $269.1 million on December 31, 2024, down from $329.4 million a year earlier.
- Howard W. Robin, President and CEO of Nektar, stated that they are on track to report topline data for rezpegaldesleukin in 2025.
- Nektar's net loss for 2024 was $119.0 million, a decrease from a loss of $276.1 million in the previous year.
Insights by Ground AI
Does this summary seem wrong?
85 Articles
85 Articles
Kingsport Times-News+22 Reposted by 22 other sources
FGI INDUSTRIES ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2024 RESULTS CONFERENCE CALL DATE
EAST HANOVER, N.J., March 13, 2025 /PRNewswire/ -- FGI Industries Ltd. (Nasdaq: FGI) ("FGI" or the "Company"), a leading global supplier of kitchen and bath products, today announced that it will issue financial results for the fourth quarter and full-year…
Docusign Announces Fourth Quarter and Fiscal Year 2025 Financial Results
SAN FRANCISCO, March 13, 2025 /PRNewswire/ -- Docusign, Inc. (NASDAQ: DOCU) today announced results for its fourth quarter and fiscal year ended January 31, 2025. Prepared remarks and the news release with the financial results will be accessible on Docusign's…
·Tucson, United States
Read Full Article
Coverage Details
Total News Sources85
Leaning Left16Leaning Right4Center30Last UpdatedBias Distribution60% Center
Bias Distribution
- 60% of the sources are Center
60% Center
L 32%
C 60%
Factuality
To view factuality data please Upgrade to Premium
